Day One concludes Mersana Therapeutics acquisition
The tender offer expired on 5 January 2026. The transaction involved purchasing all outstanding shares of Mersana at $25 per share in cash, along with one non-tradable contingent
This is claimed to become the first fully dedicated small-interfering RNA (siRNA) enzymatic-ligation manufacturing facility. The facility expansion is intended to increase capacity, lower production expenses, and enable
The Digital Acceleration of Toxicity Assessment with Mechanistic and AI-driven Predictions (DATAMAP) project, in collaboration with Baylor College of Medicine, Amgen, Torch Bio and Cincinnati Children’s Hospital Medical